Steven Harr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

They ultimately confessed to a crime, dna evidence later prove they did not commit. We learned a lot since the central park case not to jump to conclusions. Reporter since then interrogation techniques have changed and are recorded. Detectives can still lie but not about everything. The public is also now more skeptical and not assuming an arrest equals guilt but the police insist the victims version of events in this case have merit. Both the victim and the father, the witness say the last gun used. Were still searching for that gun. Theres a lot more to dhoin case. Reporter among whats left ...

Key Insights Significantly high institutional ownership implies Sana Biotechnology's stock price is sensitive to their...

By Zaeem Shoaib Sana Biotechnology's stock jumped after the company discussed early Phase 1 trial results from its SC291 CAR T-cell therapy at the JPMorgan...

Sana Biotechnology went public before testing any treatments in people. The cell and gene therapy startup won't launch clinical trials for at least a year. Noted life sciences VCs Flagship Pioneering and Arch Venture Partners were its biggest shareholders pre-IPO. Cell and gene editing startup Sana Biotechnology's shares jumped more than 40% on its first day of trading, making one of its investors' stakes worth more than $1.5 billion.  The company sold 23.5 million shares at $25 apiece Thursday. Its stock price was up 40.40% at the end of the first day of trading, closing at $35.10 per share...